Current Clinical Trial Landscape of OX40 Agonists.

Authors

Rashi Yadav, Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St., 2N35, Portland, OR, 97213, USAFollow
William L. Redmond, Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St., 2N35, Portland, OR, 97213, USAFollow

Document Type

Article

Publication Date

3-29-2022

Publication Title

Current oncology reports

Keywords

oregon; portland; eacri; CTLA-4; Cancer immunotherapy; Clinical trials; OX40; PD-1; T cell

Abstract

PURPOSE OF REVIEW: Despite the efficacy of immune checkpoint blockade (ICB) immunotherapy, most cancer patients still develop progressive disease necessitating additional treatment options. One approach is ligation of the OX40 (CD134) costimulatory receptor which promotes T cell activation, effector function, and the generation of long-lived memory cells.

RECENT FINDINGS: Numerous preclinical studies have demonstrated that OX40 agonists alone or in combination with ICB (e.g., anti-PD-1, anti-PD-L1, and anti-CTLA-4) augment anti-tumor immunity. In this review, we discuss the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Recommended Citation

Yadav, Rashi and Redmond, William L., "Current Clinical Trial Landscape of OX40 Agonists." (2022). Articles, Abstracts, and Reports. 5957.
https://digitalcommons.providence.org/publications/5957